Cargando…

The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes

BACKGROUND: To determine whether 12 months of intensive medical therapy (IMT) improves HDL functionality parameters in subjects with type II diabetes (T2D). METHODS: Retrospective, randomized, and controlled 12-month IMT intervention trial that enrolled 13-subjects with T2D (age 51- years, fasting g...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashyap, Sangeeta, Kheniser, Karim, Li, Ling, Bena, James, Kasumov, Takhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002094/
https://www.ncbi.nlm.nih.gov/pubmed/27567897
http://dx.doi.org/10.1186/s12944-016-0314-4
_version_ 1782450512374792192
author Kashyap, Sangeeta
Kheniser, Karim
Li, Ling
Bena, James
Kasumov, Takhar
author_facet Kashyap, Sangeeta
Kheniser, Karim
Li, Ling
Bena, James
Kasumov, Takhar
author_sort Kashyap, Sangeeta
collection PubMed
description BACKGROUND: To determine whether 12 months of intensive medical therapy (IMT) improves HDL functionality parameters in subjects with type II diabetes (T2D). METHODS: Retrospective, randomized, and controlled 12-month IMT intervention trial that enrolled 13-subjects with T2D (age 51- years, fasting glucose 147 mg/dL, body mass index [BMI] 36.5 kg/m(2)) and nine healthy control (46-years, fasting glucose 90 mg/dL, BMI 26.5 kg/m2). Subjects with T2D underwent IMT and HDL functionality measures (pro-inflammatory index of high-density lipoprotein (pHDL)), paraoxonase one (PON1), ceruloplasmin (Cp), and myeloperoxidase (MPO) activity were performed on samples at baseline and at 12-months following IMT. RESULTS: At baseline, pHDL index was significantly higher in subjects with T2D (p < 0.001) and apolipoprotein A-1 levels were significantly lower (p = 0.013) vs. controls. After 12-months, there was a trend for improved pHDL activity (p = 0.083), as indicated by intent-to-treat analysis, but when the non-adherent subject was omitted (per-protocol), significant attenuations in pHDL activity (p = 0.040) were noted; Δ pHDL activity at 12-months was associated with Δ weight (r = 0.62, p = 0.032) and Δ fasting glucose (r = 0.65, p = 0.022). Moreover, PON1 activity significantly improved (p < 0.001). The aforementioned occurred in association with improvements in inflammatory markers (i.e., C-reactive protein & tumor necrosis factor), hemoglobin A1C, fasting glucose, triglycerides, high-density lipoprotein levels and adipokines. CONCLUSION: IMT ameliorates pHDL index and significantly improves anti-oxidative function, as measured by PON1. Improvements in weight and fasting glucose mediated the decrease in pHDL index. Pharmacological aids and lifestyle modification are required to improve cardiovascular risk factors, subsequent mortality risk, and promote T2D remission. Application of either form of therapy alone may only have relatively miniscule effects on the aforementioned factors, in relation to the aggregate.
format Online
Article
Text
id pubmed-5002094
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50020942016-08-28 The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes Kashyap, Sangeeta Kheniser, Karim Li, Ling Bena, James Kasumov, Takhar Lipids Health Dis Research BACKGROUND: To determine whether 12 months of intensive medical therapy (IMT) improves HDL functionality parameters in subjects with type II diabetes (T2D). METHODS: Retrospective, randomized, and controlled 12-month IMT intervention trial that enrolled 13-subjects with T2D (age 51- years, fasting glucose 147 mg/dL, body mass index [BMI] 36.5 kg/m(2)) and nine healthy control (46-years, fasting glucose 90 mg/dL, BMI 26.5 kg/m2). Subjects with T2D underwent IMT and HDL functionality measures (pro-inflammatory index of high-density lipoprotein (pHDL)), paraoxonase one (PON1), ceruloplasmin (Cp), and myeloperoxidase (MPO) activity were performed on samples at baseline and at 12-months following IMT. RESULTS: At baseline, pHDL index was significantly higher in subjects with T2D (p < 0.001) and apolipoprotein A-1 levels were significantly lower (p = 0.013) vs. controls. After 12-months, there was a trend for improved pHDL activity (p = 0.083), as indicated by intent-to-treat analysis, but when the non-adherent subject was omitted (per-protocol), significant attenuations in pHDL activity (p = 0.040) were noted; Δ pHDL activity at 12-months was associated with Δ weight (r = 0.62, p = 0.032) and Δ fasting glucose (r = 0.65, p = 0.022). Moreover, PON1 activity significantly improved (p < 0.001). The aforementioned occurred in association with improvements in inflammatory markers (i.e., C-reactive protein & tumor necrosis factor), hemoglobin A1C, fasting glucose, triglycerides, high-density lipoprotein levels and adipokines. CONCLUSION: IMT ameliorates pHDL index and significantly improves anti-oxidative function, as measured by PON1. Improvements in weight and fasting glucose mediated the decrease in pHDL index. Pharmacological aids and lifestyle modification are required to improve cardiovascular risk factors, subsequent mortality risk, and promote T2D remission. Application of either form of therapy alone may only have relatively miniscule effects on the aforementioned factors, in relation to the aggregate. BioMed Central 2016-08-27 /pmc/articles/PMC5002094/ /pubmed/27567897 http://dx.doi.org/10.1186/s12944-016-0314-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kashyap, Sangeeta
Kheniser, Karim
Li, Ling
Bena, James
Kasumov, Takhar
The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
title The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
title_full The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
title_fullStr The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
title_full_unstemmed The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
title_short The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
title_sort therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002094/
https://www.ncbi.nlm.nih.gov/pubmed/27567897
http://dx.doi.org/10.1186/s12944-016-0314-4
work_keys_str_mv AT kashyapsangeeta thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes
AT kheniserkarim thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes
AT liling thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes
AT benajames thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes
AT kasumovtakhar thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes
AT kashyapsangeeta therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes
AT kheniserkarim therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes
AT liling therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes
AT benajames therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes
AT kasumovtakhar therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes